You are here

Company Monitoring Page for Incyte

latest headlines for company on cafepharma

Can Jakafi hit $3B? Incyte thinks so—and it's got other launches on the way

Fierce Pharma

Thu, 02/13/20 - 11:28 pm

Tags:

Incyte, Jakafi, pemigatinib

Incyte Earnings, Revenue Beat in Q4

Yahoo/Investing.com

Thu, 02/13/20 - 11:00 am

Tags:

Incyte, earnings

Eli Lilly and Incyte Record Another Positive Clinical Trial for Olumiant Works in Eczema

Motley Fool

Thu, 02/13/20 - 12:12 am

Tags:

Eli Lilly, Incyte, olumiant, eczema, clinical trials, atopic dermatitis

Novartis nabs priority review for a blockbuster-to-be aimed at NSCLC niche — delighting Incyte execs

Endpoints

Tue, 02/11/20 - 10:28 am

Tags:

Incyte, Novartis, FDA, capmatinib, prioirty review, non-small cell lung cancer

Incyte's skin disease drug meets main goal in late-stage study

Yahoo/Reuters

Tue, 01/28/20 - 12:00 pm

Tags:

Incyte, clinical trials, atopic dermatitis, ruxolitinib

Incyte Commits $900M to MorphoSys for Rights to Lymphoma Drug

Xconomy

Mon, 01/13/20 - 11:51 pm

Tags:

Incyte, MorphoSys, lymphoma, tafasitamab

Incyte stock slammed after study fails to hit goal

Marketwatch

Thu, 01/2/20 - 11:44 pm

Tags:

Incyte, clinical trials, itacitinib, graft vs host disease

Is IBD 50 Drugmaker Incyte Stock On The Cusp Of Innovation-Fueled Growth Spurt?

Investors Business Daily

Tue, 12/3/19 - 09:47 am

Tags:

Incyte, Jakafi, innovation

FDA accepts Incyte’s NDA for priority review of pemigatinib to treat cholangiocarcinoma

Pharmaceutical Business Review

Fri, 11/29/19 - 02:24 pm

Tags:

FDA, Incyte, priority review, pemigatinib, cholangiocarcinoma

Biopharma Q3: Pfizer, Merck, Amgen, Incyte and J&J

BioSpace

Sat, 11/2/19 - 07:55 pm

Tags:

earnings, Pfizer, Merck, Amgen, Incyte, JNJ

Why the Earnings Surprise Streak Could Continue for Incyte (INCY)

Yahoo/Zacks.com

Sat, 10/19/19 - 01:28 pm

Tags:

Incyte, earnings

Incyte's cash cow Jakafi chugs along with positive frontline results for GVHD

Endpoints

Wed, 10/16/19 - 12:23 pm

Tags:

Incyte, FDA, graft vs host disease, Jakafi

3 Drug Stocks Poised for Gains After Cancer Conference

Investopedia

Sun, 10/6/19 - 12:26 pm

Tags:

ESMO, cancer, Amgen, Incyte, Bristol-Myers Squibb

ICER pulls report blasting ‘marginal’ RA drugs, citing need to rethink its approach

Fierce Pharma

Wed, 10/2/19 - 11:53 am

Tags:

ICER, JAK inhibitors, rheumatoid arthritis, AbbVie, Rinvoq, Pfizer, Xeljanz, Incyte, olumiant

Incyte announces first patient treated in phase 3 trial program evaluating Ruxolitinib cream in patients with vitiligo

Pharmaceutical Business Review

Thu, 09/26/19 - 07:42 pm

Tags:

Incyte, clinical trials, ruxolitinib, vitiligo

The Week Ahead In Biotech: Spotlight On ESMO Conference

Yahoo/Benzinga

Sun, 09/22/19 - 11:10 pm

This Could Be a Big Year for Incyte

Motley Fool

Wed, 09/18/19 - 06:52 pm

Tags:

Incyte, Jakafi, blood cancers

Novartis’ lung cancer drug edges closer to market after FDA grants fast review

Pharmaforum

Fri, 09/6/19 - 12:27 pm

Tags:

Novartis, Incyte, FDA, breakthrough therapy, non-small cell lung cancer

Zai builds cancer combo strategy with rights to Incyte's PD-1 mAb

BioCentury

Wed, 07/3/19 - 12:07 am

Tags:

Zai Lab, China, PD-1 inhibitors, Incyte

Look here, FDA: Eli Lilly touts Olumiant safety data for unapproved high dose

Fierce Pharma

Wed, 06/12/19 - 06:43 pm

Tags:

Eli Lilly, Incyte, olumiant, safety data, Humira, rheumatoid arthritis

Pages

last 30 twitter posts